The company produces and sells around 160 specialized and general medicines based on a diverse portfolio that includes the endocrine, circulatory, and urinary systems. Since 2004, it has built an R&D infrastructure by securing key research personnel and expanding research facilities through corporate innovation in global new drug R&D. It is currently researching Anti-TNF biopharmaceuticals and new target anticancer immunotherapeutic antibodies that strengthen the body's anticancer immune response to treat cancer.

HanAll Biopharma has established itself as a leader in innovative drug development, leveraging its global clinical development capabilities and antibody research expertise. The company's R&D prowess is characterized by the following key aspects: HanAll Biopharma invests over 10% of its annual revenue into R&D projects, demonstrating a strong commitment to innovation. This sustained investment has enabled the company to expand its focus to immunology, oncology, neurology, and ophthalmology, developing innovative medicines for diseases with high unmet medical needs. The company's research infrastructure includes the Suwon Bio Research Center and its U.S. subsidiary, HPI (HanAll Pharmaceutical International), both established in 2007. These facilities serve as the core of HanAll's R&D efforts, driving drug development achievements through antibody research and global clinical trial capabilities. HanAll's pipeline includes several promising candidates. Its lead asset, HL161 (batoclimab), an anti-FcRn antibody, is in Phase 3 and Phase 2 trials worldwide for various autoimmune diseases. Another key asset, HL036 (tanfanercept), a TNF inhibitor, is undergoing Phase 3 clinical studies for dry eye disease in the US and China. The company's R&D excellence has been recognized internationally. In 2017, HanAll secured significant technology export contracts with China's Harbor BioMed and the U.S.'s Roivant, including a $500 million deal for HL161, marking the first large-scale technology export of a novel target antibody drug developed in South Korea. HanAll Biopharma continues to foster innovation through open collaboration, partnering with various domestic and international companies to develop treatments for conditions such as dry eye syndrome, autoimmune diseases, and neuroimmune disorders. The company's commitment to R&D has been further acknowledged by its receipt of the 2024 National Industry Award for Research and Development excellence, highlighting its contributions to the biopharmaceutical industry.

Public

Pharma, Bio